

Poster presentation

Open Access

Efficacy of linezolid (LZD), vancomycin (VAN) and its combinations with rifampin (RIF) in the treatment of experimental meningitis due to methicillin-resistant *Staphylococcus aureus*

Carmen Garrigósc*, M Eugenia Pachón-Ibáñez, Carmen Cabellos, Óscar Murillo, Enriqueta Force, Ferrán Taberner, Marta Cardiel and Francesc Gudiol

Address: IDIBELL, Hospital Universitari de Bellvitge, L' Hospitalet de Llobregat, Barcelona, 08907, Spain

Email: Carmen Garrigósc* - garrigos.vacas@hotmail.com

* Corresponding author

from Infectious diseases of the nervous system: pathogenesis and worldwide impact
Paris, France. 10–13 September 2008

Published: 23 September 2008

BMC Proceedings 2008, 2(Suppl 1):P21

This abstract is available from: <http://www.biomedcentral.com/1753-6561/2/S1/P21>

© 2008 Garrigósc et al; licensee BioMed Central Ltd.

Objective

To study the *in vitro* and *in vivo* activity of LZD, VAN and its combinations with RIF in a rabbit meningitis model, caused by two strains of *S. aureus* with different susceptibilities to glycopeptides.

Methods

In vitro

MICs (mg/L): Strain A (LZD = 2, VAN = 1, RIF = 0.018) and B (LZD = 4, VAN = 8, RIF = 512). The bactericidal activity and synergy (time-kill curves) were studied over 24 h. Drugs were tested for a range of concentrations according to their MICs and achievable human serum levels (1/4x-4xMIC) against both strains.

In vivo

New Zealand rabbits (2.5–3 kg) were used, with an inoculum of 8.5–9 Log cfu/mL. PK/PD parameters (blood and CSF) were determined (C_{max} [mg/L]; AUC [mg.h/L]; t_{1/2} [h]; t > MIC [h]; AUC/MIC) after a single dose of each antimicrobial on infected rabbits. In the therapy experiments, animals (n = 6 per schedule) were grouped in untreated (CON), or treated with LZD (20 mg/kg), VAN (25 mg/kg every 4 hours, 4 doses), RIF (15 mg/kg) every 24 hours (1 dose), LZD+RIF or VAN+RIF. CSF variables analyzed at 0, 4, 6 and 24 h of treatment were: bacterial

concentration (Log₁₀ cfu/mL), WBC (cells/mL), lactate (mmol/L) and protein concentration (g/L). Statistical Analysis: Wilcoxon and Anova test were used.

Results

In vitro

The following schedules were bactericidal: Strain A: LZD (4xMIC) and the following combinations RIF (2xMIC)+LZD(4xMIC), RIF (1xMIC)+LZD (1/2xMIC), RIF (1/2xMIC)+LZD (1xMIC); and strain B: VAN (4xMIC, 2xMIC) and the combinations of both drugs with RIF.

In vivo

PK/PD C_{max} (µg/mL): Blood: LZD 20.84, VAN 59.59, RIF 52.38, CSF: LZD 4.64, VAN 4.12; RIF 1.22. Percentage of penetration: LZD 19%; VAN 15%; RIF 3.8%.

Bacterial concentration (0, 4, 6, 24 h): Strain A: CON (4.94, 4.48, 4.76, 4.65), LZD (4.96, 4.71, 4.81, 4.27), VAN (5.25, 4.62, 4.30, 4.95), RIF (5.32, 5.65, 5.19, 4.80), LDZ+RIF (4.85, 4.90, 4.82, 4.17) and VAN+RIF (5.34, 5.30, 5.36, 4.61); Strain B: CON (5.19, 4.67, 4.81, 4.37), LZD (4.85, 4.37, 4.18, 3.67), VAN (5.00, 5.63, 4.79, 4.79) and LDZ+RIF (5.02, 4.90, 4.53, 4.21). For Strain B, LZD and LZD+RIF significantly reduced bacterial concentra-

tion (24 h vs. 0 h, $p < 0.05$). LZD reduced the CSF lactate and proteins levels (24 h vs. 0 h, $p < 0.05$).

Conclusion

In this model of experimental meningitis caused by a GISA strain, linezolid and linezolid plus rifampin were effective reducing the CSF bacterial concentration and inflammatory parameters.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

